A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
Phase 2
120
about 7.1 years
18+
2 sites in MI, PA
What this study is about
Researchers are testing the safety and effectiveness of a treatment called Afimkibart (also known as RO7790121) for people with atopic dermatitis who have already taken part in other afimkibart clinical trials. The trial will last 2591 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Afimkibart
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Percentage of Participants with Adverse Events
Secondary: Change From Baseline (in Parent Study) in Eczema Area and Severity Index (EASI) Score at Each Visit, Change from Baseline (in the parent study) in Dermatology Life Quality Index (DLQI) at Each Visit, Change from Baseline (in the parent study) in Participant-Oriented Eczema Measure (POEM) at Each Visit, Percent Change From Baseline (in Parent Study) in EASI Score at Each Visit
Dermatology